Oklo’s shares have soared approximately 265% over the past year, extending a 30% gain already in 2026. This dramatic run has driven the company’s implied valuation to around $15 billion, reflecting growing investor enthusiasm for advanced nuclear technology despite the absence of current revenue.

Oklo is developing small fast-spectrum reactors designed for efficient fuel recycling and plans to own and operate these units under long-term power purchase agreements to secure predictable cash flows. In parallel, its Atomic Alchemy subsidiary recently inked an agreement with the Department of Energy to build a radioisotope pilot facility, positioning Oklo to serve markets in medical and industrial isotopes.

The company has not yet obtained a design license from the Nuclear Regulatory Commission nor operated a full-scale Aurora reactor. Progress through the NRC’s multi-stage review is ongoing, but any delays or technical setbacks could significantly impact Oklo’s timeline to commercialization and revenue generation.

With a multibillion-dollar market capitalization and no current sales, Oklo’s valuation appears rich based on future potential alone. Near-term upside may be constrained by unproven deliverables, while long-term investors who anticipate successful NRC approval and first-of-a-kind reactor deployments over the next five to ten years could still see significant returns. Cautious investors may consider broader nuclear energy ETFs for diversified exposure to the sector.